Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response and those with partial or no response?

2010 ◽  
Vol 2010 ◽  
pp. 417-419
Author(s):  
D.R. Jones
Keyword(s):  
Esophageal Cancer ◽  
Complete Response ◽  
Neoadjuvant Chemoradiation ◽  
Pattern Of Recurrence

scholarly journals Hedgehog Pathway as a Potential Intervention Target in Esophageal Cancer

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 821 ◽  
Author(s):  
Da Wang ◽  
Peter Nagle ◽  
Helena Wang ◽  
Justin Smit ◽  
Hette Faber ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Treatment Resistance ◽  
Complete Response ◽  
Therapy Resistance ◽  
Neoadjuvant Chemoradiation ◽  
Control Group ◽  
Cancer Stemness ◽  
Anti Cancer ◽  
Sphere Formation

Esophageal cancer (EC) is an aggressive disease with a poor prognosis. Treatment resistance is a major challenge in successful anti-cancer therapy. Pathological complete response after neoadjuvant chemoradiation (nCRT) is low, thus requiring therapy optimization. The Hedgehog (HH) pathway has been implicated in therapy resistance, as well as in cancer stemness. This article focusses on the HH pathway as a putative target in the treatment of EC. Immunohistochemistry on HH members was applied to EC patient material followed by modulation of 3D-EC cell cultures, fluorescence-activated cell sorting (FACS), and gene expression analysis after HH pathway modulation. Sonic Hedgehog (SHH) and its receptor Patched1 (PTCH1) were significantly enriched in EC resection material of patients with microresidual disease (mRD) after receiving nCRT, compared to the control group. Stimulation with SHH resulted in an up-regulation of cancer stemness in EC sphere cultures, as indicated by increased sphere formation after sorting for CD44+/CD24− EC cancer stem-like cell (CSC) population. On the contrary, inhibiting this pathway with vismodegib led to a decrease in cancer stemness and both radiation and carboplatin resistance. Our results strengthen the role of the HH pathway in chemoradiotherapy resistance. These findings suggest that targeting the HH pathway could be an attractive approach to control CSCs.

Complete response to neoadjuvant chemoradiation therapy for esophageal cancer does not confer a survival advantage

2004 ◽  
Vol 11 (S2) ◽  
pp. S55-S55
Author(s):  
C. R. Schmidt ◽  
J. L. Tarpley ◽  
J. R. Roberts ◽  
A. S. Pearson ◽  
M. C. Kelley ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Complete Response ◽  
Neoadjuvant Chemoradiation ◽  
Chemoradiation Therapy ◽  
Survival Advantage ◽  
Neoadjuvant Chemoradiation Therapy

scholarly journals Pathologically Complete Response after Triple Therapy in Locally Advanced Esophageal Cancer in a Hereditary Hemorrhagic Telangiectasia Patient

2020 ◽  
Vol 13 (1) ◽  
pp. 176-181
Author(s):  
Robin Park ◽  
Alisdair Philp ◽  
Alykhan S. Nagji ◽  
Anup Kasi
Keyword(s):  
Esophageal Cancer ◽  
Hereditary Hemorrhagic Telangiectasia ◽  
Tumor Response ◽  
Locally Advanced ◽  
Complete Response ◽  
Neoadjuvant Chemoradiation ◽  
Advanced Esophageal Cancer ◽  
Endoscopic Screening ◽  
Hereditary Hemorrhagic Telangiectasia Patient ◽  
Locally Advanced Esophageal Cancer

Hereditary hemorrhagic telangiectasia (HHT) is a disorder characterized by vascular manifestations including mucocutaneous and visceral telangiectasias and arteriovenous malformations. Herein we present the case of a relatively young patient with HHT with an incidentally discovered locally advanced esophageal cancer on endoscopic screening and pathologically complete response after neoadjuvant chemoradiation. This case highlights an unusual tumor response to chemoradiation in locally advanced esophageal cancer, and the surveillance care of HHT patients.

Sign in / Sign up

Export Citation Format

Share Document